Hepatitis C virus

Summary

Alias: hepatitis C virus HCV, human hepatitis C virus, human hepatitis C virus HCV, human hepatitis virus C HCV, post-transfusion hepatitis non A non B virus, HCV, Hepatitis C, human hepatitis virus HCV

Top Publications

  1. Vitrenko Y, Kostenko I, Kulebyakina K, Sorochynska K. Prevalence of human pegivirus-1 and sequence variability of its E2 glycoprotein estimated from screening donors of fetal stem cell-containing material. Virol J. 2017;14:167 pubmed publisher
    ..of the Flaviviridae family whose genomic organization and mode of cellular entry is similar to that of hepatitis C virus (HCV)...
  2. Zhao Q, Hu Z, Zhang J, Jiang J, Ma Y, Li J, et al. Dual Roles of Two Isoforms of Autophagy-related Gene ATG10 in HCV-Subgenomic replicon Mediated Autophagy Flux and Innate Immunity. Sci Rep. 2017;7:11250 pubmed publisher
    ..Here, we focus on interactions between autophagy mechanism and innate-immune-response in HCV-subgenomic replicon cells to find a mechanism linking the two pathways...
  3. Karakoc A, Berkem R, Irmak H, Demiroz A, Yenicesu I, Ertugrul N, et al. Investigation of an algorithm for anti HCV EIA reactivity in blood donor screening in Turkey in the absence of nucleic acid amplification screening. Transfus Apher Sci. 2017;56:732-737 pubmed publisher
    In this study we aimed to propose an algorithm for initial anti HCV EIA reactive blood donations in Turkey where nucleic acid amplification tests are not yet obligatory for donor screening...
  4. Grove J, Hu K, Farquhar M, Goodall M, Walker L, Jamshad M, et al. A new panel of epitope mapped monoclonal antibodies recognising the prototypical tetraspanin CD81. Wellcome Open Res. 2017;2:82 pubmed publisher
    ..to numerous physiological and pathological processes, including acting as a critical entry receptor for hepatitis C virus (HCV)...
  5. Sibulesky L, Kling C, Limaye A, Johnson C. Is Kidney Donor Profile Index (KDPI) Valid for Hepatitis C Aviremic Kidneys?. Ann Transplant. 2017;22:663-664 pubmed
    ..This scoring system is based on 10 donor factors including Hepatitis C virus (HCV) status from serological or NAT testing. The donor HCV status (i.e...
  6. Johnson A, Grosely R, Petrov A, Puglisi J. Dynamics of IRES-mediated translation. Philos Trans R Soc Lond B Biol Sci. 2017;372: pubmed publisher
    ..The simplest types of IRESs are typified by the cricket paralysis virus intergenic region (CrPV IGR) and hepatitis C virus (HCV) IRESs, both of which independently form high-affinity complexes with the small (40S) ribosomal subunit ..
  7. Churchill C, Polowczyk J. Cryoglobulinemia: A Rare Cause of Digital Gangrene After Elective Foot Surgery. J Foot Ankle Surg. 2017;56:674-679 pubmed publisher
    ..of a patient with normal preoperative vascular examination findings and a history significant for untreated hepatitis C. The patient underwent revisional second toe arthrodesis and plantar plate repair with pin fixation...
  8. Gheorghe L, Sporea I, Iacob S, Sirli R, Trifan A, Diculescu M, et al. Position Paper on Treatment of Hepatitis C in Romania 2017. Part Two. J Gastrointestin Liver Dis. 2017;26:309-317 pubmed publisher
    b>Hepatitis C virus (HCV) infection is a common condition with endemic prevalence in some areas of the world. In Romania, the mean prevalence is about 3%...
  9. Tsutsumi Y, Nakayama C, Kamada K, Kikuchi R, Kudo D, Ito S, et al. Efficacy and prognosis of antiviral therapy on hepatitis C following treatment of lymphoma in HCV-positive diffuse large-cell lymphoma. Ann Hematol. 2017;96:2057-2061 pubmed publisher
    The purpose of this study is to study the usefulness of post-remission antiviral therapy in cases of HCV-RNA-positive diffuse large-cell lymphoma...
  10. Batchelder A, Cockerham Colas L, Peyser D, Reynoso S, Soloway I, Litwin A. Perceived benefits of the hepatitis C peer educators: a qualitative investigation. Harm Reduct J. 2017;14:67 pubmed publisher
    Although opioid-dependent patients are disproportionately impacted by hepatitis C (HCV), many do not receive treatment...

Detail Information

Publications122 found, 100 shown here

  1. Vitrenko Y, Kostenko I, Kulebyakina K, Sorochynska K. Prevalence of human pegivirus-1 and sequence variability of its E2 glycoprotein estimated from screening donors of fetal stem cell-containing material. Virol J. 2017;14:167 pubmed publisher
    ..of the Flaviviridae family whose genomic organization and mode of cellular entry is similar to that of hepatitis C virus (HCV)...
  2. Zhao Q, Hu Z, Zhang J, Jiang J, Ma Y, Li J, et al. Dual Roles of Two Isoforms of Autophagy-related Gene ATG10 in HCV-Subgenomic replicon Mediated Autophagy Flux and Innate Immunity. Sci Rep. 2017;7:11250 pubmed publisher
    ..Here, we focus on interactions between autophagy mechanism and innate-immune-response in HCV-subgenomic replicon cells to find a mechanism linking the two pathways...
  3. Karakoc A, Berkem R, Irmak H, Demiroz A, Yenicesu I, Ertugrul N, et al. Investigation of an algorithm for anti HCV EIA reactivity in blood donor screening in Turkey in the absence of nucleic acid amplification screening. Transfus Apher Sci. 2017;56:732-737 pubmed publisher
    In this study we aimed to propose an algorithm for initial anti HCV EIA reactive blood donations in Turkey where nucleic acid amplification tests are not yet obligatory for donor screening...
  4. Grove J, Hu K, Farquhar M, Goodall M, Walker L, Jamshad M, et al. A new panel of epitope mapped monoclonal antibodies recognising the prototypical tetraspanin CD81. Wellcome Open Res. 2017;2:82 pubmed publisher
    ..to numerous physiological and pathological processes, including acting as a critical entry receptor for hepatitis C virus (HCV)...
  5. Sibulesky L, Kling C, Limaye A, Johnson C. Is Kidney Donor Profile Index (KDPI) Valid for Hepatitis C Aviremic Kidneys?. Ann Transplant. 2017;22:663-664 pubmed
    ..This scoring system is based on 10 donor factors including Hepatitis C virus (HCV) status from serological or NAT testing. The donor HCV status (i.e...
  6. Johnson A, Grosely R, Petrov A, Puglisi J. Dynamics of IRES-mediated translation. Philos Trans R Soc Lond B Biol Sci. 2017;372: pubmed publisher
    ..The simplest types of IRESs are typified by the cricket paralysis virus intergenic region (CrPV IGR) and hepatitis C virus (HCV) IRESs, both of which independently form high-affinity complexes with the small (40S) ribosomal subunit ..
  7. Churchill C, Polowczyk J. Cryoglobulinemia: A Rare Cause of Digital Gangrene After Elective Foot Surgery. J Foot Ankle Surg. 2017;56:674-679 pubmed publisher
    ..of a patient with normal preoperative vascular examination findings and a history significant for untreated hepatitis C. The patient underwent revisional second toe arthrodesis and plantar plate repair with pin fixation...
  8. Gheorghe L, Sporea I, Iacob S, Sirli R, Trifan A, Diculescu M, et al. Position Paper on Treatment of Hepatitis C in Romania 2017. Part Two. J Gastrointestin Liver Dis. 2017;26:309-317 pubmed publisher
    b>Hepatitis C virus (HCV) infection is a common condition with endemic prevalence in some areas of the world. In Romania, the mean prevalence is about 3%...
  9. Tsutsumi Y, Nakayama C, Kamada K, Kikuchi R, Kudo D, Ito S, et al. Efficacy and prognosis of antiviral therapy on hepatitis C following treatment of lymphoma in HCV-positive diffuse large-cell lymphoma. Ann Hematol. 2017;96:2057-2061 pubmed publisher
    The purpose of this study is to study the usefulness of post-remission antiviral therapy in cases of HCV-RNA-positive diffuse large-cell lymphoma...
  10. Batchelder A, Cockerham Colas L, Peyser D, Reynoso S, Soloway I, Litwin A. Perceived benefits of the hepatitis C peer educators: a qualitative investigation. Harm Reduct J. 2017;14:67 pubmed publisher
    Although opioid-dependent patients are disproportionately impacted by hepatitis C (HCV), many do not receive treatment...
  11. Bellon M, Nicot C. Telomere Dynamics in Immune Senescence and Exhaustion Triggered by Chronic Viral Infection. Viruses. 2017;9: pubmed publisher
    ..exhaustion in chronic viruses known to cause human disease: Epstein-Barr virus (EBV), Hepatitis B/C/D virus (HBV/HCV/HDV), human herpesvirus 8 (HHV-8), human immunodeficiency virus (HIV), human T-cell leukemia virus type I (HTLV-I), ..
  12. Younossi Z, Chan H, Dan Y, Lee M, Lim Y, Kruger E, et al. Impact of Ledipasvir/Sofosbuvir on the Work Productivity of Genotype 1 Chronic Hepatitis C Patients in Asia. J Viral Hepat. 2017;: pubmed publisher
    Chronic, untreated hepatitis C virus (HCV) infection is associated with a poor clinical prognosis and a detrimental impact on patients' lives, including on work productivity...
  13. Sokol R, Early J, Barner A, Gottfried S, Gumpert R, Libaridian L, et al. Implementation of a multidisciplinary, team-based model to treat chronic hepatitis C in the primary care setting: Lessons learned. Healthc (Amst). 2017;: pubmed publisher
    b>Hepatitis C virus (HCV) is the most common blood-borne virus in the U.S., and its incidence continues to rise...
  14. Hansen J, Juul Nielsen M, Nyström K, Leeming D, Lagging M, Norkrans G, et al. PRO-C3: a new and more precise collagen marker for liver fibrosis in patients with chronic hepatitis C. Scand J Gastroenterol. 2017;:1-5 pubmed publisher
    ..significant fibrosis and cirrhosis remains important in treatment and follow-up of patients with chronic hepatitis C Infection (CHC)...
  15. Marot A, Henrion J, Knebel J, Moreno C, Deltenre P. Alcoholic liver disease confers a worse prognosis than HCV infection and non-alcoholic fatty liver disease among patients with cirrhosis: An observational study. PLoS ONE. 2017;12:e0186715 pubmed publisher
    ..Cirrhosis is a heterogeneous clinical condition that includes patients at wide-ranging stages of severity. The role of the underlying liver disease on patient prognosis remains unclear...
  16. Debes J, van Tilborg M, Groothuismink Z, Hansen B, Schulze zur Wiesch J, von Felden J, et al. Levels of Cytokines in Serum Associate With Development of Hepatocellular Carcinoma in Patients With HCV Infection Treated With Direct-acting Antivirals. Gastroenterology. 2017;: pubmed publisher
    Concern has arisen about the development of hepatocellular carcinoma (HCC) in patients with hepatitis C virus (HCV) infection treated with direct-acting antivirals (DAAs)...
  17. Frey A, Piras Straub K, Walker A, Timm J, Gerken G, Herzer K. The influence of immunosuppressants on direct-acting antiviral therapy is dependent on hepatitis C virus genotype. Transpl Infect Dis. 2017;: pubmed publisher
    ..The influence of immunosuppressive agents on the efficacy of DAAs has not been clarified...
  18. Chirikov V, Shaya F, Onukwugha E, Mullins C, dosReis S, Howell C. Tree-based Claims Algorithm for Measuring Pretreatment Quality of Care in Medicare Disabled Hepatitis C Patients. Med Care. 2017;55:e104-e112 pubmed publisher
    ..we provide an easy-to-follow framework on the implementation of random forests and apply it to identify quality of care (QC) patterns correlated with treatment receipt among Medicare disabled patients with hepatitis C virus (HCV).
  19. Townsend S, Monga M, Nightingale P, Mutimer D, Elsharkawy A, Holt A. Hepatitis C Virus Recurrence Occurs Earlier in Patients Receiving Donation After Circulatory Death Liver Transplant Grafts Compared With Those Receiving Donation After Brainstem Death Grafts. Transplant Proc. 2017;49:2129-2134 pubmed publisher
    b>Hepatitis C virus (HCV)-related cirrhosis remains the commonest indication for liver transplantation worldwide, yet few studies have investigated the impact of donation after circulatory death (DCD) graft use on HCV recurrence and ..
  20. Rickles M, Rebeiro P, Sizemore L, Juarez P, Mutter M, Wester C, et al. Tennessee's In-State Vulnerability Assessment for a 'Rapid Dissemination of HIV or HCV Infection' Event Utilizing Data about the Opioid Epidemic. Clin Infect Dis. 2017;: pubmed publisher
    Knowing which factors contribute to county-level vulnerability to an HIV/Hepatitis C (HCV) outbreak, and which counties are most vulnerable, guide public health and clinical interventions...
  21. Bang B, Elmasry S, Saito T. Organ system view of the hepatic innate immunity in HCV infection. J Med Virol. 2016;88:2025-2037 pubmed publisher
    ..Although immunity against HCV infection is known to be inadequate as most cases transitions to chronicity, approximately 25% of acute infection ..
  22. Jung J, Feldman R, Cheong C, Du P, Leslie D. Coverage for hepatitis C drugs in Medicare Part D. Am J Manag Care. 2016;22:SP220-6 pubmed
    The recent arrival of new hepatitis C virus (HCV) drugs has brought fiscal pressures onto Medicare Part D; spending on HCV drugs in Part D jumped from $283 million in 2013 to $4.5 billion in 2014...
  23. Phusanti S, Manosudprasit K, Sungkanuparph S. Long-Term Liver Diseases after Initiation of Antiretroviral Therapy in HIV-Infected Patients with and without HBV or HCV Coinfection. J Int Assoc Provid AIDS Care. 2017;16:194-200 pubmed publisher
    Coinfection of hepatitis B virus (HBV) or hepatitis C virus (HCV) with HIV is common and associated with increased mortality and increased risk of progression to chronic liver disease...
  24. Shawa I, Felmlee D, Hegazy D, Sheridan D, Cramp M. Exploration of potential mechanisms of hepatitis C virus resistance in exposed uninfected intravenous drug users. J Viral Hepat. 2017;24:1082-1088 pubmed publisher
    A rare outcome following exposure to hepatitis C virus (HCV) is a lack of observable infection as clinically measured by HCV RNA- or HCV-recognizing antibodies. The population who exhibit this trait is termed exposed uninfected (EU)...
  25. Doi A, Sakamori R, Tahata Y, Urabe A, Morishita N, Yamada R, et al. Frequency of, and factors associated with, hepatitis B virus reactivation in hepatitis C patients treated with all-oral direct-acting antivirals: Analysis of a Japanese prospective cohort. Hepatol Res. 2017;47:1438-1444 pubmed publisher
    Several case reports have shown that hepatitis B virus (HBV) reactivation developed in hepatitis C patients with a current or previous HBV infection during direct-acting antiviral (DAA) treatment, which led to severe hepatitis or death ..
  26. Henderson C, Madden A, Kelsall J. 'Beyond the willing & the waiting' - The role of peer-based approaches in hepatitis C diagnosis & treatment. Int J Drug Policy. 2017;: pubmed publisher
    ..role, value and importance of peer-based programmatic approaches for ensuring the effective roll-out of the new hepatitis C (HCV) treatments among those most affected - that is, people who inject drugs (PWID)...
  27. Estevez J, Chen V, Podlaha O, Li B, Le A, Vutien P, et al. Differential Serum Cytokine Profiles in Patients with Chronic Hepatitis B, C, and Hepatocellular Carcinoma. Sci Rep. 2017;7:11867 pubmed publisher
    ..and hepatocellular carcinoma (HCC), most cases of which are related to either hepatitis B virus (HBV) or hepatitis C virus (HCV)...
  28. Song S, Gong S, Singh P, Lyu J, Bai Y. The interaction between mitochondria and oncoviruses. Biochim Biophys Acta. 2018;1864:481-487 pubmed publisher
    ..In this context, oncogenesis by oncoviruses like Hepatitis B virus (HBV), Hepatitis C virus (HCV), Human papilloma virus (HPV), Human Immunodeficiency virus (HIV) and Epstein-Barr virus (EBV) will be ..
  29. Irwin L, Kotton C, Elias N, Palafox J, Basler D, Shao S, et al. Utilization of increased risk for transmission of infectious disease donor organs in solid organ transplantation: Retrospective analysis of disease transmission and safety. Transpl Infect Dis. 2017;: pubmed publisher
    ..Serologies and nucleic acid testing (NAT) for hepatitis C virus (HCV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV) are used in microbiologic screening ..
  30. Wijarnpreecha K, Chesdachai S, Jaruvongvanich V, Ungprasert P. Hepatitis C virus infection and risk of Parkinson's disease: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2017;: pubmed publisher
    b>Hepatitis C virus (HCV) infection is one of the most common infections worldwide. Recent epidemiologic studies have suggested that patients with HCV infection might be at an increased risk of Parkinson's disease...
  31. Buggisch P, Vermehren J, Mauss S, Günther R, Schott E, Pathil A, et al. Real-world effectiveness of 8-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C. J Hepatol. 2017;: pubmed publisher
    Ledipasvir/sofosbuvir (LDV/SOF) for 8 to 24 weeks is approved for the treatment of chronic hepatitis C virus infection (HCV)...
  32. Vitrone M, Andini R, Mattucci I, Maiello C, Atripaldi L, Durante Mangoni E, et al. Direct antiviral treatment of chronic hepatitis C in heart transplant recipients. Transpl Infect Dis. 2017;: pubmed publisher
    Direct-acting antiviral agents (DAAs) are a safe and effective treatment for chronic hepatitis C (CHC)...
  33. Kasprzak A, Rogacki K, Adamek A, Sterzyńska K, Przybyszewska W, Seraszek Jaros A, et al. Tissue expression of β-catenin and E- and N-cadherins in chronic hepatitis C and hepatocellular carcinoma. Arch Med Sci. 2017;13:1269-1280 pubmed publisher
    The role of Wnt/ β -catenin signaling pathway in HCV-associated hepatocellular carcinogenesis is still unknown.
  34. Cheng L, Hui C, Reddy G, Ding Y, Shi P. Internode morphometrics and allometry of Tonkin Cane Pseudosasa amabilis. Ecol Evol. 2017;7:9651-9660 pubmed publisher
    ..Results showed that length (L), hollow radius (HR), hollow area (HA), hollow cylinder volume (HCV), total cylinder volume (TCV), density (De), and weight (W) all presented positive skewed distribution in varying ..
  35. Smolders E, Smit C, de Kanter C, Dofferhoff A, Arends J, Brinkman K, et al. Management of drug interactions with direct-acting antivirals in Dutch HIV/hepatitis C virus-coinfected patients: adequate but not perfect. HIV Med. 2017;: pubmed publisher
    Direct-acting antivirals (DAAs) for treatment of chronic hepatitis C virus (HCV) infection can cause drug-drug interactions (DDIs) with combination antiretroviral therapy (cART) and non-cART co-medication...
  36. Bharti A, Letendre S, Wolfson T, Clifford D, Collier A, Gelman B, et al. Clinical variables identify seronegative HCV co-infection in HIV-infected individuals. J Clin Virol. 2011;52:328-32 pubmed publisher
    A substantial number of people living with HIV (PLWH) are co-infected with Hepatitis C Virus (HCV) but have a negative screening HCV antibody test (seronegative HCV infection, or SN-HCV).
  37. Herrero R, Pineda J, Rivero Juárez A, Echbarthi M, Real L, Camacho A, et al. Common haplotypes in CD209 promoter and susceptibility to HIV-1 infection in intravenous drug users. Infect Genet Evol. 2016;45:20-25 pubmed publisher
    ..with risk of HIV-1 infection in a cohort of Spanish male intravenous drug users (IDU) infected with hepatitis C virus (HCV) and to characterize the phenotypic effects of the associated variants...
  38. van der Meer A, Feld J, Hofer H, Almasio P, Calvaruso V, Fernandez Rodriguez C, et al. Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication. J Hepatol. 2017;66:485-493 pubmed publisher
    The risk of hepatocellular carcinoma (HCC) is reduced but not eradicated among patients with hepatitis C virus (HCV)-induced advanced hepatic fibrosis who attained sustained viral response (SVR)...
  39. Janjua N, Chong M, Kuo M, Woods R, Wong J, Yoshida E, et al. Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada. J Hepatol. 2017;66:504-513 pubmed publisher
    ..carcinoma (HCC) risk after sustained virological response (SVR) to interferon-based treatment of hepatitis C virus (HCV) infection...
  40. da Silva R, de Carvalho I, de Matos R, Yamasaki L, Bittar C, Rahal P, et al. Evidence of bottleneck effect on hepatitis C virus transmission between a couple under interferon based therapy. Infect Genet Evol. 2017;47:87-93 pubmed publisher
    Issues on the correlation of viral genetic diversity and treatment response to the hepatitis C infection remain uncertain...
  41. Weisberg I, Jacobson I. Primer on Hepatitis C Virus Resistance to Direct-Acting Antiviral Treatment: A Practical Approach for the Treating Physician. Clin Liver Dis. 2017;21:659-672 pubmed publisher
    Treatment of hepatitis C virus has been vastly transformed by the arrival of all-oral, interferon-free, direct-acting antiviral regimens...
  42. Sarkar M, Dodge J, Greenblatt R, Kuniholm M, Dehovitz J, Plankey M, et al. Reproductive Aging and Hepatic Fibrosis Progression in Human Immunodeficiency Virus/Hepatitis C Virus-Coinfected Women. Clin Infect Dis. 2017;65:1695-1702 pubmed publisher
    ..However, prior studies of estrogen and liver fibrosis lack serial fibrosis measures, adjustment for age, or longitudinal observations in coinfected populations...
  43. Imoto S, Kim S, Amano K, Iio E, Yoon S, Hirohata S, et al. Serum IFN-λ3 Levels Correlate with Serum Hepatitis C Virus RNA Levels in Symptomatic Patients with Acute Hepatitis C. Dig Dis. 2017;35:531-540 pubmed publisher
    ..SNPs), upstream of the interferon-λ (IFNL) 3 gene, are associated with the spontaneous clearance of hepatitis C virus (HCV) in symptomatic patients with acute hepatitis C (AHC)...
  44. Goetsch M, Tamhane A, Varshney M, Kapil A, Overton E, Towns G, et al. Direct-Acting Antivirals in Kidney Transplant Patients: Successful Hepatitis C Treatment and Short-Term Reduction in Urinary Protein/Creatinine Ratios. Pathog Immun. 2017;2:366-375 pubmed publisher
    The role of Hepatitis C Virus (HCV) clearance in kidney graft survival is unknown. We examined short-term trends of protein/creatinine (P/C) ratios in HCV-infected kidney transplant recipients treated with direct-acting antivirals (DAAs).
  45. Cantalupo P, Katz J, Pipas J. Viral sequences in human cancer. Virology. 2018;513:208-216 pubmed publisher
    ..In addition to the reported associations of Hepatitis B and C virus (HBV & HCV) with liver cancer, and Human papillomaviruses (HPV) with cervical cancer and a subset of head and neck cancers, we ..
  46. Innes H, Barclay S, Hayes P, Fraser A, Dillon J, Stanley A, et al. The risk of hepatocellular carcinoma in cirrhotic patients with hepatitis C and sustained viral response: role of the treatment regimen. J Hepatol. 2017;: pubmed publisher
    ..HCC) occurrence in patients with advanced liver disease, after receipt of interferon (IFN)-free therapy for hepatitis C virus (HCV) infection...
  47. Carvalho R, Atta A, de Oliveira I, Santos T, Santos J, Schinoni M, et al. Adiponectin levels and insulin resistance among patients with chronic hepatitis C. Acta Trop. 2018;178:258-263 pubmed publisher
    Chronic hepatitis C virus (HCV) infection is associated with insulin resistance (IR), rapid disease progression, and decreased virological response to antiviral treatment...
  48. Sikorska K, Stalke P, Romanowski T, Rzepko R, Bielawski K. Liver steatosis correlates with iron overload but not with HFE gene mutations in chronic hepatitis C. Hepatobiliary Pancreat Dis Int. 2013;12:377-84 pubmed
    Liver steatosis and iron overload, which are frequently observed in chronic hepatitis C (CHC), may contribute to the progression of liver injury...
  49. Beltra J, Decaluwe H. Cytokines and persistent viral infections. Cytokine. 2016;82:4-15 pubmed publisher
    Intracellular pathogens such as the human immunodeficiency virus, hepatitis C and B or Epstein-Barr virus often cause chronic viral infections in humans...
  50. Macparland S, Ma X, Chen L, Khattar R, Cherepanov V, Selzner M, et al. Lipopolysaccharide and Tumor Necrosis Factor Alpha Inhibit Interferon Signaling in Hepatocytes by Increasing Ubiquitin-Like Protease 18 (USP18) Expression. J Virol. 2016;90:5549-60 pubmed publisher
    ..innate inflammatory responses is a hallmark of chronic viral infections such as, hepatitis B virus and hepatitis C virus (HCV)...
  51. Mansoor S, Javed A, Ali A, Mansoor A. Heterogeneous genomic locations within NS3, NS4A and NS4B identified for genotyping and subtyping of Hepatitis C virus: A simple genome analysis approach. Infect Genet Evol. 2016;44:61-8 pubmed publisher
    b>Hepatitis C virus (HCV) displays excessive genetic heterogeneity and exists in several genotypes and subtypes. Characterizing these genotypes and subtypes becomes extremely important for diagnostic and epidemiological reasons...
  52. He Q, Zhang Q, Zhang D. Efficacy and Safety of Ribavirin with Sofosbuvir Plus Ledipasvir in Patients with Genotype 1 Hepatitis C: A Meta-Analysis. Dig Dis Sci. 2016;61:3108-3117 pubmed
    ..SL) have exhibited promising results for the treatment of patients with hepatitis C virus (HCV) genotype 1 infection...
  53. Farid C, Sheikh W, Swelem R, El Ghitany E. Frequency of FOXP3+ Regulatory T-cells in the Blood of Chronic Hepatitis C Patients with Immune Mediated Skin Manifestations; Relationship to Hepatic Condition and Viral Load. Clin Lab. 2016;62:2339-2348 pubmed publisher
    Chronic hepatitis C (CHC) infection causes a wide range of immune mediated hepatic and extrahepatic manifestations. Cutaneous manifestations constitute a major portion of the latter group...
  54. Grgurevic I, Bokun T, Bozin T, Matić V, Haberle S, Sporea I. Non-invasive diagnosis of portal hypertension in cirrhosis using ultrasound based elastography. Med Ultrason. 2017;19:310-317 pubmed publisher
    ..These recommendations refer primarily to patients with viral aetiology of chronic liver disease (hepatitis C), while additional studies are required for other aetiologies...
  55. Castelli G, Pelosi E, Testa U. Liver Cancer: Molecular Characterization, Clonal Evolution and Cancer Stem Cells. Cancers (Basel). 2017;9: pubmed publisher
    ..cirrhosis related to various etiologies: hepatitis B virus (HBV) infection (frequent in Asia and Africa), hepatitis C virus (HCV), chronic alcohol abuse, or metabolic syndrome (frequent in Western countries)...
  56. Khokhar N, Nasir H, Amir M, Hassan S, Khan K, Ahmed M. Lymphoepithelioma-Like Carcinoma of the Esophagus: A Rare Tumor. J Coll Physicians Surg Pak. 2017;27:S114-S116 pubmed publisher
    ..We report the case of a 45-year female who had been treated for hepatitis C and esophageal tuberculosis and recovered fully from these conditions...
  57. Bae S, Sim T, Lim C, Kim D, Lee J, Park Y, et al. HM10660A, a long-acting hIFN-α-2b, is a potent candidate for the treatment of hepatitis C through an enhanced biological half-life. Int J Pharm. 2017;534:89-96 pubmed publisher
    Interferon-α (IFN-α) has been widely used for the treatment of infections due to the hepatitis C virus (HCV). Because of the short half-life of IFN-α in serum, it must be administered three times per week...
  58. Afsheen Z, Ahmad B, Bashir S. Hospital-visiting pregnant women signal an increased spread of hepatitis C infection in Khyber Pakhtunkhwa region of Pakistan. Virol J. 2017;14:195 pubmed publisher
    ..each district and thus provides a large sample-size of healthy pregnant women of known medical history for Hepatitis C Virus (HCV) surveillance...
  59. Rizza S, Nehra V, Temesgen Z. Sofosbuvir/ledipasvir fixed-dose combination for treatment of chronic hepatitis C virus infection in children. Drugs Today (Barc). 2017;53:447-451 pubmed publisher
    ..recently approved sofosbuvir and the fixed-dose combination of ledipasvir/sofosbuvir for the treatment of hepatitis C virus (HCV) infection in children ages 12 to 17...
  60. Rahman M, Roy D, Debnath C, Roy A, Muqueet M, Kabir M, et al. Acute Kidney Injury in Patients with Acute Viral Hepatitis: A Study in a Tertiary Care Hospital. Mymensingh Med J. 2017;26:790-796 pubmed
    ..acute viral hepatitis A, 21% acute viral hepatitis B and 52% acute viral hepatitis E but no case of acute viral hepatitis C was found in this study. Acute kidney injury (AKI) developed in 6 of 27 patients with acute viral hepatitis A...
  61. Blum P, Pircher J, Merkle M, Czermak T, Ribeiro A, Mannell H, et al. Arterial thrombosis in the context of HCV-associated vascular disease can be prevented by protein C. Cell Mol Immunol. 2017;14:986-996 pubmed publisher
    b>Hepatitis C virus (HCV) infection is a major problem worldwide. HCV is not limited to liver disease but is frequently complicated by immune-mediated extrahepatic manifestations such as glomerulonephritis or vasculitis...
  62. Goldaracena N, Spetzler V, Echeverri J, Kaths J, Cherepanov V, Persson R, et al. Inducing Hepatitis C Virus Resistance After Pig Liver Transplantation-A Proof of Concept of Liver Graft Modification Using Warm Ex Vivo Perfusion. Am J Transplant. 2017;17:970-978 pubmed publisher
    ..b>Hepatitis C virus (HCV) is dependent on the presence of miRNA(microRNA)-122...
  63. Hu Z, Qin J, Follmann D. Semiparametric pseudoscore for regression with multidimensional but incompletely observed regressor. Stat Med. 2018;37:207-217 pubmed publisher
    ..Numerical performance is explored by Monte Carlo simulations and a study on treating hepatitis C patients with HIV coinfection. Published 2017. This article is a U.S...
  64. Stoeck I, Lee J, Tabata K, Romero Brey I, Paul D, Schult P, et al. Hepatitis C Virus Replication Depends on Endosomal Cholesterol Homeostasis. J Virol. 2018;92: pubmed publisher
    Similar to other positive-strand RNA viruses, hepatitis C virus (HCV) causes massive rearrangements of intracellular membranes, resulting in a membranous web (MW) composed of predominantly double-membrane vesicles (DMVs), the presumed ..
  65. Reid M, Price J, Tien P. Hepatitis C Virus Infection in the Older Patient. Infect Dis Clin North Am. 2017;31:827-838 pubmed publisher
    b>Hepatitis C virus (HCV) is the most common blood-borne infection in the United States and is of concern in older adults...
  66. Liu T, Chung R, Wang S, Fang C, Tsou H, Shih C, et al. Missense mutation at CLDN8 associated with a high plasma interferon gamma-inducible protein 10 level in methadone-maintained patients with urine test positive for morphine. PLoS ONE. 2017;12:e0187639 pubmed publisher
    ..level and prolonged electrocardiography QT-interval in methadone maintenance treatment (MMT) patients with HIV or HCV infection...
  67. Lafferty L, Rance J, Treloar C. Who goes first? Understanding hepatitis C risk among injecting networks in the prison setting. Drug Alcohol Depend. 2017;183:96-101 pubmed publisher
    b>Hepatitis C (HCV) is a blood-borne virus that is most commonly transmitted through shared injecting equipment. Due to the criminalisation of injecting drug use, HCV is highly prevalent among those incarcerated...
  68. Mullenbach R, Weber S, Krawczyk M, Zimmer V, Sarrazin C, Lammert F, et al. A frequent variant in the human bile salt export pump gene ABCB11 is associated with hepatitis C virus infection, but not liver stiffness in a German population. BMC Gastroenterol. 2012;12:63 pubmed
    ..levels were shown to be significantly associated with rates and risk of cirrhosis in patients with chronic hepatitis C virus (HCV) infection treated with pegylated interferon-α2 and ribavirin, suggesting a potential role for bile ..
  69. Lombana L, Ortega Atienza S, Gomez Gutierrez J, Yélamos B, Peterson D, Gavilanes F. The deletion of residues 268-292 of E1 impairs the ability of HCV envelope proteins to induce pore formation. Virus Res. 2016;217:63-70 pubmed publisher
    We have obtained a chimeric protein containing the ectodomains of hepatitis C virus (HCV) envelope proteins but lacking the region 268-292 of E1...
  70. Vegna S, Grégoire D, Moreau M, Lassus P, Durantel D, Assenat E, et al. NOD1 Participates in the Innate Immune Response Triggered by Hepatitis C Virus Polymerase. J Virol. 2016;90:6022-35 pubmed publisher
    b>Hepatitis C virus (HCV) triggers innate immunity signaling in the infected cell...
  71. Yi W, Zhang P, Liang Y, Zhou Y, Shen H, Fan C, et al. T-bet-mediated Tim-3 expression dampens monocyte function during chronic hepatitis C virus infection. Immunology. 2017;150:301-311 pubmed publisher
    b>Hepatitis C virus (HCV) induces a high rate of chronic infection via dysregulation of host immunity...
  72. Lin C, Dutta S, Asatryan A, Chiu Y, Wang H, Clifton J, et al. Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of ABT-493: A First-In-Human Study. J Pharm Sci. 2017;106:645-651 pubmed publisher
    ABT-493 is a hepatitis C virus nonstructural protein 3/4A protease inhibitor with pangenotypic antiviral activity...
  73. Puhr R, Wright S, Hoy J, Templeton D, Durier N, Matthews G, et al. Retrospective study of hepatitis C outcomes and treatment in HIV co-infected persons from the Australian HIV Observational Database. Sex Health. 2017;14:345-354 pubmed publisher
    ..of direct-acting antivirals (DAAs) is expected to drastically improve the treatment uptake and cure rate of hepatitis C virus (HCV)...
  74. Gane E, Shiffman M, Etzkorn K, Morelli G, Stedman C, Davis M, et al. Sofosbuvir-velpatasvir with ribavirin for 24 weeks in hepatitis C virus patients previously treated with a direct-acting antiviral regimen. Hepatology. 2017;66:1083-1089 pubmed publisher
    The optimal retreatment strategy for patients chronically infected with hepatitis C virus who experience virologic failure after treatment with direct-acting antiviral-based therapies remains unclear...
  75. Assoumou S, Tasillo A, Leff J, Schackman B, Drainoni M, Horsburgh C, et al. The cost-effectiveness of one-time hepatitis C screening strategies among adolescents and young adults in primary care settings. Clin Infect Dis. 2017;: pubmed publisher
    High hepatitis C virus (HCV) rates have been reported in young people who inject drugs (PWID)...
  76. Kirk G, Dandorf S, Li H, Chen Y, Mehta S, Piggott D, et al. Differential Relationships among Circulating Inflammatory and Immune Activation Biomediators and Impact of Aging and Human Immunodeficiency Virus Infection in a Cohort of Injection Drug Users. Front Immunol. 2017;8:1343 pubmed publisher
    ..Multivariate regression analyses were employed, adjusting for age, sex, body mass index, smoking, hepatitis C virus co-infection, injection drug use, comorbidities, and HIV status (for all participants), and HIV viral load, ..
  77. Koffas A, Karani J, Williams R. Coil embolization for intrahepatic haemorrhage following liver biopsy in a patient with hepatitis C virus infection and hepatic microaneurysms. Oxf Med Case Reports. 2017;2017:omx073 pubmed publisher
    ..Hepatic vasculitis is reported in chronic hepatitis C virus (HCV) infection and an association between hepatitis C and PAN is described...
  78. Chen J, Xu X, Huang Z, Luo Y, Tang L, Jiang J. BEAMing LAMP: single-molecule capture and on-bead isothermal amplification for digital detection of hepatitis C virus in plasma. Chem Commun (Camb). 2018;54:291-294 pubmed publisher
    ....
  79. Simmons R, Ireland G, Irving W, Hickman M, Sabin C, Ijaz S, et al. Establishing the cascade of care for hepatitis C in England-benchmarking to monitor impact of direct acting antivirals. J Viral Hepat. 2017;: pubmed publisher
    Little is known about engagement and retention in care of people diagnosed with chronic hepatitis C (HCV) in England...
  80. Bellan M, Sainaghi P, Minh M, Minisini R, Molinari L, Baldrighi M, et al. Gas6 as a predictor of esophageal varices in patients affected by hepatitis C virus related-chronic liver disease. Biomark Med. 2017;: pubmed publisher
    ..Plasma Gas6 was tested as an alternative to Baveno VI criteria (liver stiffness <20 kPa and platelet count >150 × 109/l) in an endoscopy-sparing strategy...
  81. Ochiai Y, Sano E, Okamoto Y, Yoshimura S, Makita K, Yamamuro S, et al. Efficacy of ribavirin against malignant glioma cell lines: Follow-up study. Oncol Rep. 2018;39:537-544 pubmed publisher
    ..employed as an antiviral agent against RNA and DNA viruses and has become the standard agent used for chronic hepatitis C in combination with interferon-α2a...
  82. Pacella I, Timperi E, Accapezzato D, Martire C, Labbadia G, Cavallari E, et al. IFN-α promotes rapid human Treg contraction and late Th1-like Treg decrease. J Leukoc Biol. 2016;100:613-23 pubmed publisher
    ..effect in vitro and in vivo, as early as after 2 d of pegylated IFN/ribavirin therapy in patients with chronic hepatitis C. Such activities result in the decline, at d 2, in circulating regulatory T cell frequency and specifically of ..
  83. van der Hoeven B, Oudshoorn D, Koster A, Snijder E, Kikkert M, BARCENA M. Biogenesis and architecture of arterivirus replication organelles. Virus Res. 2016;220:70-90 pubmed publisher
    ..g. coronaviruses, picornaviruses and hepatitis C virus. In the last years, electron tomography has revealed substantial differences between the structures induced ..
  84. Saeed M, Olsen M, Powderly W, Presti R. Diabetes Mellitus is Associated With Higher Risk of Developing Decompensated Cirrhosis in Chronic Hepatitis C Patients. J Clin Gastroenterol. 2017;51:70-76 pubmed
    To investigate the association of diabetes with risk of decompensated cirrhosis in patients with chronic hepatitis C (CHC).
  85. Bedimo R, Abodunde O. Metabolic and Cardiovascular Complications in HIV/HCV-Co-infected Patients. Curr HIV/AIDS Rep. 2016;13:328-339 pubmed
    Fifteen to thirty percent of HIV-infected persons in North America and Europe are co-infected with chronic hepatitis C (HCV)...
  86. Uchida Y, Kouyama J, Naiki K, Sugawara K, Inao M, Imai Y, et al. "Reversi-type virologic failure" involved in the development of non-structural protein 5A resistance-associated variants (RAVs) in patients with genotype 1b hepatitis C carrying no signature RAVs at baseline. Hepatol Res. 2017;47:1397-1407 pubmed publisher
    ..of daclatasvir/asunaprevir was inferior in patients with non-structural protein 5A (NS5A)-R30Q mutant hepatitis C virus strains at baseline, compared with those with wild-type strains, even though the half maximal effective ..
  87. Dever J, Ducom J, Ma A, Nguyen J, Liu L, Herrin A, et al. Engagement in Care of High-Risk Hepatitis C Patients with Interferon-Free Direct-Acting Antiviral Therapies. Dig Dis Sci. 2017;62:1472-1479 pubmed publisher
    The extent to which hepatitis C (HCV) treatment uptake is improved following introduction of interferon-free direct-acting antiviral (DAA) treatments is unknown...
  88. Saxena V, Khungar V, Verna E, Levitsky J, Brown R, Hassan M, et al. Safety and efficacy of current direct-acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: Results from the HCV-TARGET study. Hepatology. 2017;66:1090-1101 pubmed publisher
    ..of clinical trials with direct-acting antiviral regimens with or without ribavirin as treatment of chronic hepatitis C virus in solid organ transplant recipients are limited...
  89. Tomkins A, Lee V. Intervention to improve management of acute hepatitis C infection in a UK sexual health clinic. Int J STD AIDS. 2017;:956462417727193 pubmed publisher
    A case note review was conducted for all newly-diagnosed acute hepatitis C virus (HCV)-infected patients attending our sexual health clinic pre- and post-implementation of an HCV clinic proforma between January 2010 and September 2016...
  90. Wang M, Wang Y, Feng X, Wang R, Wang Y, Zeng H, et al. Contribution of hepatitis B virus and hepatitis C virus to liver cancer in China north areas: Experience of the Chinese National Cancer Center. Int J Infect Dis. 2017;65:15-21 pubmed publisher
    The aim of this study was to determine the impact of hepatitis B virus (HBV) and/or hepatitis C virus (HCV) on primary liver cancer (PLC) in China north areas...
  91. Sangiorgi D, Perrone V, Buda S, Boglione L, Cariti G, Lefevre C, et al. Epidemiology, patient profile, and health care resource use for hepatitis C in Italy. Clinicoecon Outcomes Res. 2017;9:609-616 pubmed publisher
    ..patient and antiviral drug characteristics, and to estimate the health care consumption rates and related costs for the management of patients affected by hepatitis C virus (HCV) infection by using data from routine clinical practice.
  92. Ardesia M, Costantino G, Mondello P, Alibrandi A, Fries W. Serology of Viral Infections and Tuberculosis Screening in an IBD Population Referred to a Tertiary Centre of Southern Italy. Gastroenterol Res Pract. 2017;2017:4139656 pubmed publisher
    ..The aim of our study was to assess the immune status for hepatitis B, varicella, mononucleosis, and cytomegalovirus infection together with the determination of the hepatitis C and tuberculosis status in Southern Italy.
  93. Rozera G, Fabbri G, Lorenzini P, Mastrorosa I, Timelli L, Zaccarelli M, et al. Peripheral blood HIV-1 DNA dynamics in antiretroviral-treated HIV/HCV co-infected patients receiving directly-acting antivirals. PLoS ONE. 2017;12:e0187095 pubmed publisher
    ..dynamics of peripheral blood mononuclear cells (PBMC)- associated total HIV-1 DNA in successfully ART-treated HIV/HCV co-infected patients receiving DAA treatment and to explore possible virological hypotheses underlying the ..
  94. Kumthip K, Yang D, Li N, Zhang Y, Fan M, Sethuraman A, et al. Pivotal role for the ESCRT-II complex subunit EAP30/SNF8 in IRF3-dependent innate antiviral defense. PLoS Pathog. 2017;13:e1006713 pubmed publisher
    ..of EAP30 also impaired the establishment of an antiviral state against vesicular stomatitis virus and hepatitis C virus, which are of distinct viral families...
  95. Nowak K, Witzke O, Sotiropoulos G, Benko T, Fiedler M, Timm J, et al. Transplantation of Renal Allografts From Organ Donors Reactive for HCV Antibodies to HCV-Negative Recipients: Safety and Clinical Outcome. Kidney Int Rep. 2017;2:53-59 pubmed publisher
    ..The aim of this study was to analyze the outcome of renal transplant donation from hepatitis C virus (HCV)-positive donors.
  96. Barocas J, Wang J, White L, Tasillo A, Salomon J, Freedberg K, et al. Hepatitis C Testing Increased Among Baby Boomers Following The 2012 Change To CDC Testing Recommendations. Health Aff (Millwood). 2017;36:2142-2150 pubmed publisher
    In 2012 the Centers for Disease Control and Prevention recommended routine testing for hepatitis C for people born in the period 1945-65...
  97. Tseng C, Lin C, Chen Y, Tseng C, Lee J, Lee J. Discovery of naphtho[1,2-d]oxazole derivatives as potential anti-HCV agents through inducing heme oxygenase-1 expression. Eur J Med Chem. 2018;143:970-982 pubmed publisher
    A number of naphtho[1,2-d]oxazole derivatives were synthesized and evaluated for their anti-HCV virus activity...
  98. Shimelis T, Tassachew Y, Tadewos A, Hordofa M, Amsalu A, Tadesse B, et al. Coinfections with hepatitis B and C virus and syphilis among HIV-infected clients in Southern Ethiopia: a cross-sectional study. HIV AIDS (Auckl). 2017;9:203-210 pubmed publisher
    Hepatitis B virus (HBV) and hepatitis C virus (HCV) are hepatotropic viruses of public health significance worldwide...
  99. Puig Basagoiti F, Fukuhara T, Tamura T, Ono C, Uemura K, Kawachi Y, et al. Human Cathelicidin Compensates for the Role of Apolipoproteins in Hepatitis C Virus Infectious Particle Formation. J Virol. 2016;90:8464-77 pubmed publisher
    ..apolipoproteins (ApoA, -C, and -E) have been shown to redundantly participate in the formation of infectious hepatitis C virus (HCV) particles during the assembly process, although their precise role in the viral life cycle is not well ..
  100. Takyar V, Surana P, Kleiner D, Wilkins K, Hoofnagle J, Liang T, et al. Noninvasive markers for staging fibrosis in chronic delta hepatitis. Aliment Pharmacol Ther. 2017;45:127-138 pubmed publisher
    Serum fibrosis markers are useful in staging chronic hepatitis B (HBV) and C (HCV) virus but have not been evaluated in chronic hepatitis D virus (HDV).
  101. Merli M, Galli L, Marinaro L, Ariaudo A, Messina E, Uberti Foppa C, et al. Pharmacokinetics of dolutegravir and rilpivirine in combination with simeprevir and sofosbuvir in HIV/hepatitis C virus-coinfected patients with liver cirrhosis. J Antimicrob Chemother. 2017;72:812-815 pubmed publisher
    ..C trough ) of dolutegravir and rilpivirine used in combination with simeprevir and sofosbuvir in HIV/hepatitis C virus (HCV)-coinfected patients with liver cirrhosis...